ListedMainboardHospital & Healthcare ServicesNEPHROPLUS

Nephrocare Health Services IPO

Nephrocare Health Services IPO is a mainboard IPO raising ₹871 Cr at ₹438 – ₹460 a share. It listed on 17 Dec 2025 and trades at ₹692 today, +50.4% against its issue price of ₹460. It was subscribed 14× in total.

460
Issue price
692
Price now
+50.4%
Since issue price
17 Dec 2025
Listed on
14×Subscribed (final) · all exchanges

14.0 times more demand than shares on offer

populated partly populated we hold nothing here — the tab says why

How its cohort has done

103 mainboard issues listed in 2025 that we can price today. This is the group this issue belongs to.

+9.1%
Median return since issue price
46.6%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

How the book finished

The category split is the number worth reading, not the total.

QIB27×
Non-institutional24×
Retail2.31×

QIB: 27× their allocation. Retail: 2.31×.

See the full split, sub-category by sub-category →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidQIB, non-institutional and retail, with sub-splits
How demand built over timeOnly one reading so far; the series builds as bidding runs
Price-point demand curveLive only — NSE stops serving this once bidding closes
Lead managers and registrar5 banks
Official documents4 documents
Performance since listingComputed from our own daily closes

What happens when

8 Dec 2025Pre-apply opens
10 Dec 2025Bidding opens
12 Dec 2025Bidding closes
16 Dec 2025Allotment finalised — you find out what you got
16 Dec 2025Money refunded to unsuccessful bidders
17 Dec 2025Shares list and start trading
23 Jan 2026UPI mandate expires

Track NEPHROCARE HEALTH SERV L

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.